Guardant Health [GH] vs Exact Sciences [EXAS] Detailed Stock Comparison
Guardant Health
NASDAQ
Loading...
Exact Sciences
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Guardant Health wins in 7 metrics, Exact Sciences wins in 11 metrics, with 0 ties. Exact Sciences appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Guardant Health | Exact Sciences | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -15.26 | -7.33 | Guardant Health |
| Price-to-Book Ratio | -22.08 | 3.14 | Guardant Health |
| Debt-to-Equity Ratio | -4.37 | 102.73 | Guardant Health |
| PEG Ratio | -20.01 | -120.56 | Exact Sciences |
| EV/EBITDA | -18.07 | 120.57 | Guardant Health |
| Profit Margin (TTM) | -49.93% | -34.19% | Exact Sciences |
| Operating Margin (TTM) | -45.75% | 0.34% | Exact Sciences |
| EBITDA Margin (TTM) | N/A | 0.34% | N/A |
| Return on Equity | 312.48% | -35.51% | Guardant Health |
| Return on Assets (TTM) | -19.57% | -1.39% | Exact Sciences |
| Free Cash Flow (TTM) | $-274.94M | $74.55M | Exact Sciences |
| 1-Year Return | 87.00% | -28.10% | Guardant Health |
| Price-to-Sales Ratio (TTM) | 8.16 | 2.64 | Exact Sciences |
| Enterprise Value | $7.57B | $9.44B | Exact Sciences |
| EV/Revenue Ratio | 9.14 | 3.21 | Exact Sciences |
| Gross Profit Margin (TTM) | 65.01% | 69.35% | Exact Sciences |
| Revenue per Share (TTM) | $7 | $16 | Exact Sciences |
| Earnings per Share (Diluted) | $-3.35 | $-5.45 | Guardant Health |
| Beta (Stock Volatility) | 1.44 | 0.93 | Exact Sciences |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Guardant Health vs Exact Sciences Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Guardant Health | 1.07% | 30.93% | 6.71% | 30.11% | 22.14% | 70.70% |
| Exact Sciences | -0.17% | -14.18% | -23.44% | -22.75% | -21.74% | -28.00% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Guardant Health | 87.00% | 0.09% | -36.54% | 85.72% | 85.72% | 85.72% |
| Exact Sciences | -28.10% | -4.03% | -51.96% | 78.68% | 853.26% | 1,579.92% |
Performance & Financial Health Analysis: Guardant Health vs Exact Sciences
| Metric | GH | EXAS |
|---|---|---|
| Market Information | ||
| Market Cap | $6.76B | $7.76B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 4,168,170 | 4,605,740 |
| 90 Day Avg. Volume | 2,645,913 | 3,261,747 |
| Last Close | $54.81 | $40.92 |
| 52 Week Range | $20.14 - $55.10 | $38.81 - $72.83 |
| % from 52W High | -0.53% | -43.81% |
| All-Time High | $181.07 (Feb 08, 2021) | $159.54 (Jan 25, 2021) |
| % from All-Time High | -69.73% | -74.35% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.31% | 0.16% |
| Quarterly Earnings Growth | 0.31% | 0.16% |
| Financial Health | ||
| Profit Margin (TTM) | -0.50% | -0.34% |
| Operating Margin (TTM) | -0.46% | 0.00% |
| Return on Equity (TTM) | 3.12% | -0.36% |
| Debt to Equity (MRQ) | -4.37 | 102.73 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $-2.45 | $13.05 |
| Cash per Share (MRQ) | $4.19 | $4.53 |
| Operating Cash Flow (TTM) | $-238,546,000 | $305.61M |
| Levered Free Cash Flow (TTM) | $-131,174,000 | $140.26M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Guardant Health vs Exact Sciences
| Metric | GH | EXAS |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -15.26 | -7.33 |
| Forward P/E | -20.01 | -120.56 |
| PEG Ratio | -20.01 | -120.56 |
| Price to Sales (TTM) | 8.16 | 2.64 |
| Price to Book (MRQ) | -22.08 | 3.14 |
| Market Capitalization | ||
| Market Capitalization | $6.76B | $7.76B |
| Enterprise Value | $7.57B | $9.44B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 9.14 | 3.21 |
| Enterprise to EBITDA | -18.07 | 120.57 |
| Risk & Other Metrics | ||
| Beta | 1.44 | 0.93 |
| Book Value per Share (MRQ) | $-2.45 | $13.05 |
Financial Statements Comparison: Guardant Health vs Exact Sciences
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | GH | EXAS |
|---|---|---|
| Revenue/Sales | $203.47M | $706.79M |
| Cost of Goods Sold | $74.72M | $206.24M |
| Gross Profit | $128.75M | $500.55M |
| Research & Development | $88.52M | $105.31M |
| Operating Income (EBIT) | $-111.04M | $-89.76M |
| EBITDA | $-83.84M | $-36.86M |
| Pre-Tax Income | $-94.87M | $-100.99M |
| Income Tax | $290,000 | $224,000 |
| Net Income (Profit) | $-95.16M | $-101.22M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | GH | EXAS |
|---|---|---|
| Cash & Equivalents | $698.57M | $347.13M |
| Total Current Assets | $927.03M | $1.37B |
| Total Current Liabilities | $225.75M | $502.47M |
| Long-Term Debt | $1.28B | $2.49B |
| Total Shareholders Equity | $-250.79M | $2.40B |
| Retained Earnings | $-2.67B | $-4.60B |
| Property, Plant & Equipment | $140.50M | $126.66M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | GH | EXAS |
|---|---|---|
| Operating Cash Flow | $-49.41M | $-36.98M |
| Capital Expenditures | $-4.46M | $-31.17M |
| Free Cash Flow | $-67.15M | $-365,000 |
| Debt Repayment | N/A | $-249.17M |
| Common Stock Repurchase | $-45.01M | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | GH | EXAS |
|---|---|---|
| Shares Short | 9.58M | 7.47M |
| Short Ratio | 4.80 | 2.55 |
| Short % of Float | 0.08% | 0.05% |
| Average Daily Volume (10 Day) | 4,168,170 | 4,605,740 |
| Average Daily Volume (90 Day) | 2,645,913 | 3,261,747 |
| Shares Outstanding | 123.99M | 185.62M |
| Float Shares | 119.55M | 187.46M |
| % Held by Insiders | 0.05% | 0.01% |
| % Held by Institutions | 0.99% | 0.99% |
Dividend Analysis & Yield Comparison: Guardant Health vs Exact Sciences
| Metric | GH | EXAS |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |